促红血球生成素药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球促红血球生成素药物市值约为 104 亿美元，预计 2024 年至 2032 年复合年增长率为 4.5%。它们复製促红血球生成素的功能，促红血球生成素是一种来自肾臟的激素，负责控制红血球的生成。这些药物主要治疗贫血，这是一种以红血球缺乏为特征的疾病。

癌症盛行率的上升极大地推动了市场的发展。世界卫生组织(WHO) 报告称，2022 年全球预计将新增2000 万癌症病例和970 万人死亡。 这凸显了对促红血球生成素药物的需求激增，促红血球生成素药物对于管理与治疗相关的贫血至关重要，从而改善患者的治疗结果和生活品质。

促红血球生成素药物配方的创新彻底改变了贫血管理。这些进步优先考虑提高促红血球生成素治疗的疗效，确保安全性并提高患者的便利性。最近的製剂，如促红血球生成素药物的缓释版本，可以减少给药频率。例如，达贝泊汀-阿尔法的半衰期延长，使得注射时间可以从先前的每週注射间隔延长到每两到三週一次。

促红血球生成素药物产业分为药品类型、药品类别、用途、配销通路和地区。

市场将药物类型分为生物相似药、第一代製剂和第二代製剂。预测表明，到 2032 年，生物相似药市场规模将达到 70 亿美元。这种价格优势使得促红血球生成素疗法更容易取得，特别是在资源有限或医疗费用较高的地区。生物相似药提供了一种经济实惠的替代方案，扩大了患者获得重要贫血治疗的机会，特别是对于那些以前无法负担原始生物药物的患者。

此市场将药物类别分为阿法依泊汀、β 型依泊汀、阿尔法达贝泊汀等。 2023 年，促红血球生成素-阿尔法细分市场创造了 37 亿美元的收入。阿尔法依泊汀擅长刺激骨髓中的红血球生成（红血球生成），使其成为治疗与慢性肾臟病 (CKD)、癌症化疗和其他疾病相关的贫血的首选。透过增强红血球的产生，阿法依泊汀减少或消除了输血的必要性，输血会带来输血反应和感染等风险。

到2032年，美国促红血球生成素药物市场规模将达到58亿美元。 2020 年，美国疾病管制与预防中心 (CDC) 记录了 1,603,844 例新癌症病例，该疾病夺走了 602,347 人的生命。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性肾臟病（CKD）盛行率上升
    • 药物配方的进步
    • 癌症发生率增加
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 药品费用高
    • 潜在的副作用
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 生物相似药
• 第一代配方
• 第二代配方

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 阿尔法依泊汀
• β-促红血球生成素
• 达贝泊汀-阿尔法
• 其他药物类别

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 癌症
• 肾臟疾病
• 神经病学
• 血液学
• 其他应用

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AstraZeneca PLC
• Amgen, Inc.
• Biocon Limited
• Celltrion, Inc.
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Intas Pharmaceuticals Ltd.
• Johnson and Johnson
• Kyowa Kirin Co., Ltd.
• LG Chem, Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

The Global Erythropoietin Drugs Market was valued at approximately USD 10.4 billion in 2023 and is projected to grow at a CAGR of 4.5% from 2024 to 2032. Erythropoietin drugs stimulate the body's production of red blood cells (RBCs). They replicate the function of erythropoietin, a hormone from the kidneys that governs RBC production. These medications primarily address anemia, a condition marked by a shortage of red blood cells.

The market is significantly driven by the rising cancer prevalence. The World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. This highlights the surging demand for erythropoietin drugs, pivotal in managing treatment-related anemia, thereby enhancing patient outcomes and life quality.

Innovations in erythropoietin drug formulations have revolutionized anemia management. These advancements prioritize boosting efficacy for ensuring safety and enhancing patient convenience in erythropoietin therapies. Recent formulations, like the extended-release versions of erythropoietin drugs, enable less frequent dosing. For instance, darbepoetin-alfa's extended half-life allows injections to be spaced out from the previous weekly schedule to once every two or three weeks.

The erythropoietin drugs industry is divided into drug type, drug class, application, distribution channel, and region.

The market categorizes drug types into biosimilars, first-generation formulations, and second-generation formulations. Projections indicate that the biosimilars segment will hit USD 7 billion by 2032. Biosimilars generally come at a lower price than their reference biologics. This price advantage makes erythropoietin therapies more accessible, especially in regions with constrained resources or elevated healthcare expenses. Offering a budget-friendly alternative, biosimilars broaden patient access to vital anemia treatments, especially for those previously unable to afford the original biologic drugs.

The market segments drug classes into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. In 2023, the epoetin-alfa segment generated USD 3.7 billion. Epoetin-alfa is adept at stimulating erythropoiesis (RBC production) in the bone marrow, making it a prime choice for anemia linked to chronic kidney disease (CKD), cancer chemotherapy, and other ailments. By enhancing RBC production, epoetin-alfa diminishes or negates the necessity for blood transfusions, which carry risks like transfusion reactions and infections.

U.S. erythropoietin drugs market size will touch USD 5.8 billion by 2032. The U.S. is home to a cutting-edge healthcare system, equipped with modern medical facilities and technologies for ensuring optimal management of erythropoietin drugs. In 2020, the Centers for Disease Control and Prevention (CDC) recorded 1,603,844 new cancer cases in the U.S., with the disease claiming 602,347 lives.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic kidney disease (CKD)
    • 3.2.1.2 Advancements in drug formulations
    • 3.2.1.3 Increasing incidence of cancer
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of drugs
    • 3.2.2.2 Potential side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Biosimilars
• 5.3 First-generation formulation
• 5.4 Second-generation formulation

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Epoetin-alfa
• 6.3 Epoetin-beta
• 6.4 Darbepoetin-alfa
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Renal diseases
• 7.4 Neurology
• 7.5 Hematology
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AstraZeneca PLC
• 10.2 Amgen, Inc.
• 10.3 Biocon Limited
• 10.4 Celltrion, Inc.
• 10.5 Dr. Reddy's Laboratories Ltd.
• 10.6 F. Hoffmann-La Roche Ltd.
• 10.7 Intas Pharmaceuticals Ltd.
• 10.8 Johnson and Johnson
• 10.9 Kyowa Kirin Co., Ltd.
• 10.10 LG Chem, Ltd.
• 10.11 Novartis AG
• 10.12 Pfizer Inc.
• 10.13 Sanofi
• 10.14 Sun Pharmaceutical Industries Ltd.
• 10.15 Teva Pharmaceutical Industries Ltd.